U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07950436) titled 'Esprit BTK Japan Post-Marketing Surveillance' on Nov. 16.

Brief Summary: Esprit BTK Japan Post-Marketing Surveillance (PMS) is a database-based PMS. The purpose of this PMS is to confirm the safety and effectiveness of the Esprit BTK Everolimus Eluting Resorbable Scaffold System for the treatment of below-the-knee artery disease in the real-world clinical setting in Japan. The Surveillance will register all patients in whom treatment with Esprit BTK was attempted.

Study Start Date: Oct. 03, 2025

Study Type: OBSERVATIONAL

Condition: Chronic Limb-Threatening Ischemia

Intervention: DEVICE: Esprit BTK Everolimus Eluting Resorbable...